



PTO/SB/088 (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/798,652
Filing Date	March 11, 2004
First Named Inventor	Yongjun Guo
Art Unit	1634
Examiner Name	Salmon, K.D.
Attorney Docket Number	3882-PO3136US01

Sheet	1	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KS	C1	Fan, C. et al., "Frequent c-myc and int-2 Overrepresentations in Nasopharyngeal carcinoma", Human Pathology 31(2):169-178 (2000)	
	C2	Ikeda Y. et al., "Meanings of c-erbB and int-2 Amplification in Superficial Esophageal Squamous Cell Carcinomas", Ann Thorac Surg 62:835-838 (1996)	
	C3	Schraml P. et al., "Combined Array Comparativ eGenomic Hybridization and Tissue Microarray Analysis Suggest PAK1 at 11q13.5-q14 as a", Am J Pathol 163(3):985-992 (2003)	
	C4	Hui R. et al., "EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in ...", Oncogene 15:1617-1623 (1997)	
	C5	Maharieva B.M. et al., "High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer", J Pathol 201:603-608 (2003)	
	C6	Galdemard C. et al., "Regulation of FGF-3 Gene Expression in Tumorigenic and Non-tumorigenic Clones of a Human Colon Carcinoma cell Line", J Bio Chem 275(23):17364-17373 (2000)	
	C7	Hajitou A. et al., "Progression in MCF-7 breast cancer cell tumorigenicity: compared effect of FGF-3 and FGF-4", Breast Cancer Research and Treatment 60:15-28 (2000)	
	C8	Fioravanti L. et al., "int-2 Oncogene Amplification and Prognosis in Node-negative Breast Carcinoma", Int J Cancer 74:620-624 (1997)	
	C9	Tseleni-Balafouta S. et al., "A comparative study of the int-2 gene product in primary and secondary parathyroid lesions", European Journal of Endocrinology 146:57-60 (2002)	
	C10	Medl M. et al., "DNA Amplification of HER-2/neu and INT-2 Oncogenes in Epithelial Ovarian Cancer", Gynecologic Oncology 59:321-326 (1995)	

Examiner Signature	/Katherine Salmon/	Date Considered	04/14/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/798,652
		Filing Date	March 11, 2004
		First Named Inventor	Yongjun Guo
		Art Unit	1634
		Examiner Name	Salmon, K.D.
Sheet 2	of 2	Attorney Docket Number	3882-PO3136US01

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KS	C11	Dobianer K. et al., "HER-2 Amplification but Not Butyrylcholinesterase Mutability Reflects Aggressiveness of European-Originated ...", Gynecologic Oncology 56:200-206 (1995)	
	C22	Ropiquet F., "Increased Expression of Fibroblast Growth Factor 6 in Human Prostatic Intraepithelial Neoplasia and Prostate Cancer", Cancer Research 60:4245-4250 (2000)	
	C13	Roh H.J. et al., "Visualization fo the Timing of Gene Amplification during Multistep Head and Neck Tumorigenesis", Cancer Research 60:6496-6502 (2000)	
	C14	Arai H. et al., "Dectection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell ..." Cancer Genetics and Cytogenetics 146:16-21 (2003)	
	C15	Dickson C. et al., "Tumorigenesis by Mouse Tumor Virus: Proviral Activation of a Cellular Gene in the Common Integration Region int-2", Cell 37:529-536 (1984)	

Examiner Signature	/Katherine Salmon/	Date Considered	04/14/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.